Unlocked Access
FULL SUPPLEMENT: Exploring The Scalp Barrier and Microbiome In Diverse Dandruff Patients
March 2025 | Volume 24 | Issue 3 | Department | 32730s1 | Copyright © March 2025
Although the exact pathophysiology of dandruff is still not completely decoded, current theories highlight the role of the microbiome on the skin surface in the patho-genesis. Several scalp microbiome...
Read MoreINDIVIDUAL ARTICLE: A Clinical Evaluation of Scalp Barrier Function, Ceramide Levels, and Microbiome in Diverse Dandruff Patients
March 2025 | Volume 24 | Issue 3 | Supplement Individual Articles | 32731s3 | Copyright © March 2025
Dandruff is a common chronic scalp condition that affects approximately half the population irrespective of their origin. Dandruff scalps are characterized by flaking skin, pruritus, and minimal ...
Read MoreFULL SUPPLEMENT: Nordic European Cutaneous Oncodermatology Management (Necom) 5: A Practical Algorithm for the Treatment And Supportive Management of Cutaneous Adverse Events in Patients Receiving Targeted Therapy for Cancer
March 2025 | Volume 24 | Issue 3 | Department | 88540s1 | Copyright © March 2025
Although cancer incidences seemingly continue to rise, ongoing advancements in cancer therapy have simultaneously contributed to improved survival. Nordic survival studies from the past decades have s...
Read MoreINDIVIDUAL ARTICLE: NECOM 5: Algorithm for the Treatment and Supportive Management of Targeted Therapy-Related Cutaneous Adverse Events
March 2025 | Volume 24 | Issue 3 | Supplement Individual Articles | 88541s3 | Copyright © March 2025
Background: The cancer burden in the Nordic European countries remains substantial, but new treatment approaches, such as targeted therapy, have increased the survival of cancer ...
Read MoreAlopecia Universalis: Never Give Up?
March 2025 | Volume 24 | Issue 3 | Case Reports | 316 | Copyright © March 2025
Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medicati...
Read MoreDifferentiating and Managing Cutaneous Lupus Erythematosus-Associated Alopecia and Patchy Alopecia Areata: Therapeutic Insights From Case Studies
March 2025 | Volume 24 | Issue 3 | Case Reports | 324 | Copyright © March 2025
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with diverse clinical manifestations, including patchy hair lossresembling alopecia areata (AA). This report describes tw...
Read MoreDisparities in Alopecia Areata and Vitiligo FDA Approved Therapies in Medicaid Formularies
March 2025 | Volume 24 | Issue 3 | Editorials | e17 | Copyright © March 2025
The Potential Risk of Povidone-Iodine in Sperm Quality: A Case Report
March 2025 | Volume 24 | Issue 3 | Case Reports | e11 | Copyright © March 2025
To report a rare case of severe oligoasthenoteratozoospermia which seems to be associated with long-term topical povidone-iodine (PVP-I) therapy. A 45-year-old man with secondary infertility was ...
Read MoreFULL SUPPLEMENT: Scalp Health & the Role of the Scalp Barrier in Dandruff and Seborrheic Dermatitis
February 2025 | Volume 24 | Issue 2 | Department | 32710 | Copyright © February 2025
Research has shown that scalp and hair health are connected, but the link is not yet fully understood or characterized. Hair growth begins within the hair follicle, about 4 mm deep in the skin.1<...
Read MoreINDIVIDUAL ARTICLE: Insights on the Impact of Scalp Barrier Condition on Hair Health
February 2025 | Volume 24 | Issue 2 | Supplement Individual Articles | s3 | Copyright © February 2025
Scalp health is essential for healthy hair growth and may be affected by intrinsic or extrinsic factors. Reactive oxygens species are key contributors to aging and can have a detrimental impact o...
Read MoreINDIVIDUAL ARTICLE: Etiology, Treatment Challenges, and the Role of Scalp and Haircare in Managing Dandruff
February 2025 | Volume 24 | Issue 2 | Supplement Individual Articles | s8 | Copyright © February 2025
Dandruff and seborrheic dermatitis are associated with a disrupted scalp barrier that contributes to irritation, pruritus, and flaking of the scalp. The flaking and itch associated with dandruff ...
Read MoreFULL SUPPLEMENT: Masterful Topical JAK Inhibitor
February 2025 | Volume 24 | Issue 2 | Department | 49140 | Copyright © February 2025
Janus kinase (JAK) inhibitors, which have been used in a range of disease states from rheumatology to gastroenterology, have been finally adopted into dermatology. These agents are rapidly changing th...
Read MoreINDIVIDUAL ARTICLE: VEHICLES MATTER: DESIGNED FOR PURPOSE
February 2025 | Volume 24 | Issue 2 | Supplement Individual Articles | 49141 | Copyright © February 2025
INDIVIDUAL ARTICLE: Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis
February 2025 | Volume 24 | Issue 2 | Supplement Individual Articles | s5 | Copyright © February 2025
Dermatology has entered the long-awaited paradigm shift from steroidal to non-steroidal therapeutics for the topical treatment of atopic dermatitis. Topical Janus kinase (JAK) inhibitors have gar...
Read MoreINDIVIDUAL ARTICLE: Ruxolitinib 1.5% Cream and the "Boxed Warning Paradox": Reappraisal of Safety Through the Lens of Pharmacokinetics
February 2025 | Volume 24 | Issue 2 | Supplement Individual Articles | s16 | Copyright © February 2025
Ruxolitinib 1.5% cream is the first-in-class topical Janus kinase (JAK) inhibitor approved for the treatment of atopic dermatitis in patients 12 years of age and older. The US Food and Drug Admin...
Read MoreVisual Assessment Tools and Therapeutic Implications for Acanthosis Nigricans
February 2025 | Volume 24 | Issue 2 | Original Article | 156 | Copyright © February 2025
Acanthosis nigricans significantly impacts individuals with skin of color. No United States Food and Drug Administration (FDA)-approved therapy exists for acanthosis nigricans. This review evalua...
Read MoreAn Unusual Case of Psoriasiform Dermatitis Treated With Dual Biologic Therapy and Literature Review
February 2025 | Volume 24 | Issue 2 | Case Reports | 207 | Copyright © February 2025
Previously believed to be of distinct immunopathogenesis, atopic dermatitis (AD) and psoriasis (PsO) spectrum may permit immunologic shifts to favor the opposing inflammatory states following bio...
Read MoreInsights Into Demographics, Comorbidities, and Risk Factors in Keloids and Hypertrophic Scars: A Retrospective Study
February 2025 | Volume 24 | Issue 2 | Features | 212 | Copyright © February 2025
Hypertrophic scars and keloids represent abnormal wound healing, manifesting as raised scars confined to or extending beyond the wound margin, respectively. Understanding the risk factors associated w...
Read MoreEvaluating Quality and Reliability of Most-Viewed TikTok Videos About Spironolactone
February 2025 | Volume 24 | Issue 2 | Features | e7 | Copyright © February 2025
A Review of Management Strategies for Erosive Pustular Dermatosis of the Scalp
February 2025 | Volume 24 | Issue 2 | Features | 217 | Copyright © February 2025
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
